UBS AM’s AstraZeneca AZN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $85.5M | Sell |
450,644
-2,261
| -0.5% | -$425K | 0.02% | 539 |
|
|
2026
Q1 | $89.3M | Buy |
452,905
+355,472
| +365% | +$68.5M | 0.02% | 529 |
|
|
2025
Q4 | $17.9M | Buy |
+97,433
| New | +$17.1M | ﹤0.01% | 887 |
|
|
2025
Q2 | – | Sell |
-4,600
| Closed | -$676K | – | 2627 |
|
|
2025
Q1 | $676K | Sell |
4,600
-87,174
| -95% | -$12.6M | ﹤0.01% | 2432 |
|
|
2024
Q4 | $12M | Buy |
+91,774
| New | +$12.8M | ﹤0.01% | 1168 |
|
|
2023
Q3 | – | Sell |
-97,100
| Closed | -$13.5M | – | 2600 |
|
|
2023
Q2 | $13.5M | Hold |
97,100
| – | – | 0.01% | 862 |
|
|
2023
Q1 | $13.5M | Buy |
+97,100
| New | +$13.1M | 0.01% | 862 |
|
|
2022
Q4 | – | Sell |
-112,250
| Closed | -$12.3M | – | 2583 |
|
|
2022
Q3 | $12.3M | Sell |
112,250
-26,400
| -19% | -$3.35M | 0.01% | 892 |
|
|
2022
Q2 | $18.3M | Buy |
138,650
+126,592
| +1,050% | +$16.6M | 0.01% | 757 |
|
|
2022
Q1 | $1.6M | Hold |
12,058
| – | – | ﹤0.01% | 1907 |
|
|
2021
Q4 | $1.4M | Hold |
12,058
| – | – | ﹤0.01% | 2038 |
|
|
2021
Q3 | $1.45M | Buy |
+12,058
| New | +$1.4M | ﹤0.01% | 1977 |
|
|
2019
Q4 | – | Sell |
-3,098
| Closed | -$276K | – | 2549 |
|
|
2019
Q3 | $276K | Buy |
3,098
+624
| +25% | +$54.1K | ﹤0.01% | 2482 |
|
|
2019
Q2 | $204K | Buy |
2,474
+220
| +10% | +$17.3K | ﹤0.01% | 2537 |
|
|
2019
Q1 | $182K | Sell |
2,254
-1,025
| -31% | -$80.8K | ﹤0.01% | 2486 |
|
|
2018
Q4 | $249K | Sell |
3,279
-551
| -14% | -$43K | ﹤0.01% | 2294 |
|
|
2018
Q3 | $303K | Buy |
3,830
+25
| +0.7% | +$1.89K | ﹤0.01% | 2282 |
|
|
2018
Q2 | $267K | Buy |
3,805
+3,573
| +1,540% | +$257K | ﹤0.01% | 2351 |
|
|
2018
Q1 | $16.2K | Sell |
232
-104
| -31% | -$7.2K | ﹤0.01% | 2554 |
|
|
2017
Q4 | $23.3K | Buy |
336
+120
| +56% | +$8.09K | ﹤0.01% | 2472 |
|
|
2017
Q3 | $14.6K | Sell |
216
-27
| -11% | -$1.71K | ﹤0.01% | 2447 |
|
|
2017
Q2 | $16.5K | Buy |
243
+195
| +406% | +$12.7K | ﹤0.01% | 2433 |
|
|
2017
Q1 | $2.96K | Sell |
48
-143
| -75% | -$8.32K | ﹤0.01% | 2428 |
|
|
2016
Q4 | $10K | Buy |
+191
| New | +$10.8K | ﹤0.01% | 2386 |
|
|
2015
Q2 | – | Sell |
-3,912
| Closed | -$268K | – | 2699 |
|
|
2015
Q1 | $268K | Sell |
3,912
-72,524
| -95% | -$5.04M | ﹤0.01% | 2324 |
|
|
2014
Q4 | $5.38M | Sell |
76,436
-8,106
| -10% | -$580K | 0.01% | 1018 |
|
|
2014
Q3 | $6.04M | Buy |
84,542
+1,243
| +1% | +$91K | 0.01% | 991 |
|
|
2014
Q2 | $6.19M | Sell |
83,299
-2,553
| -3% | -$185K | 0.01% | 981 |
|
|
2014
Q1 | $5.57M | Buy |
+85,852
| New | +$5.54M | 0.01% | 1015 |
|
Other funds holding AZN
EP
IA
UBS AM's AZN Position: Q2 2026 in Review
UBS AM reduced its AstraZeneca (AZN) stake by 0.5% in Q2 2026, selling an estimated $425K and leaving 450,644 shares worth $85.5M. The position accounts for 0.02% of the portfolio, ranked #539.
UBS AM first reported a position in AZN in Q1 2014 and has held it in 29 quarters since. The position peaked at $89.3M in Q1 2026. 1,495 funds tracked by Wall St. Rank hold AZN as of Q2 2026.
- UBS AM held 450,644 shares of AstraZeneca worth $85.5M as of Q2 2026.
- UBS AM sold 2,261 AstraZeneca shares in Q2 2026, an estimated $425K.
- AstraZeneca made up 0.02% of UBS AM's portfolio in Q2 2026, its #539 holding.
- UBS AM first reported a position in AstraZeneca in Q1 2014 and has held it in 29 quarters since.
- UBS AM's AstraZeneca position peaked at $89.3M in Q1 2026.
- 1,495 funds tracked by Wall St. Rank held AstraZeneca as of Q2 2026.
Based on UBS AM's 13F filing for Q2 2026, filed 13 Aug 2026.